Literature DB >> 1607682

Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.

B R Vowels1, M Cassin, E C Vonderheid, A H Rook.   

Abstract

Sezary syndrome (SzS), the leukemic stage of cutaneous T-cell lymphoma (CTCL), is typically a CD4+ T-cell lympho-proliferative disease characterized by numerous immunologic abnormalities, including decreased T-cell responses to antigens and mitogens, decreased natural killer and lymphocyte-activated killer cell activities, eosinophilia, and increased levels of immunoglobulins, particularly IgE and IgA. Because this constellation of abnormalities is reminiscent of the pleiotropic in vitro activities of IL-4 and IL-5, we examined the possibility that malignant T cells in SzS may be producing increased amounts of IL-4 with a concomitant decrease in IL-2 and IFN-gamma production. Such a cytokine secretion pattern would be similar to that produced by murine Th2 cells. Serum IL-4 enzyme-linked immunosorbent assay measurements revealed that 33% of SzS patients (n = 21) had levels of IL-4 significantly higher (mean, 7.2 pg/ml; range, 0-48, p less than 0.05) than normal controls (mean, 1.59; range, 0-3.1). Although the majority of tested patients had elevated serum IgE, no direct correlation between serum IL-4 levels and serum IgE levels was observed. Peripheral blood mononuclear cells (PBMC) isolated from SzS patients and stimulated with phytohemagglutinin (PHA) produced significantly higher levels of interleukin (IL)-4 and significantly lower levels of IL-2 and interferon (IFN)-gamma than did PBMC from normal controls (p less than 0.02, p less than 0.05, and p less than 0.02, respectively). PBMC from SzS patients in remission produced IL-4 and IL-2 levels similar to that of the normal controls. To determine if IFN-gamma could inhibit the increased IL-4 production by PHA-stimulated PBMC from SzS patients, IFN-gamma was added to culture at 0, 24, or 48 h prior to the addition of PHA. Significant decreases in IL-4 production were seen only in cultures incubated with IFN-gamma for 24 and 48 h prior to the addition of PHA. IL-2 levels were not affected by IFN-gamma incubation. The increased IL-4 and decreased IL-2 and IFN-gamma production by PBMC from SzS patients suggests that Sezary cells have a cytokine profile similar to murine Th2 cells. Moreover, this cytokine secretion pattern may play an integral role in the immunopathogenesis of advanced CTCL. The results also suggest that IFN-gamma be a useful component in the spectrum of therapeutic approaches to SzS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607682     DOI: 10.1111/1523-1747.ep12611877

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

1.  Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.

Authors:  Kei-ichi Yamanaka; Robert C Fuhlbrigge; Hitoshi Mizutani; Thomas S Kupper
Journal:  Arch Dermatol Res       Date:  2010-01-29       Impact factor: 3.017

Review 2.  Pruritus in cutaneous T-cell lymphoma: a review.

Authors:  Kristen Ahern; Elaine S Gilmore; Brian Poligone
Journal:  J Am Acad Dermatol       Date:  2012-01-30       Impact factor: 11.527

3.  The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Authors:  Michael J Kelly-Sell; Youn H Kim; Suzanne Straus; Bernice Benoit; Cameron Harrison; Katherine Sutherland; Randall Armstrong; Wen-Kai Weng; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

4.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

5.  Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma.

Authors:  Filiberto Cedeno-Laurent; Rei Watanabe; Jessica E Teague; Thomas S Kupper; Rachael A Clark; Charles J Dimitroff
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

6.  Sézary T-cell activating factor is a Chlamydia pneumoniae-associated protein.

Authors:  J T Abrams; E C Vonderheid; S Kolbe; D M Appelt; E J Arking; B J Balin
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

7.  Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells.

Authors:  Rei Watanabe; Ahmed Gehad; Chao Yang; Laura L Scott; Jessica E Teague; Christoph Schlapbach; Christopher P Elco; Victor Huang; Tiago R Matos; Thomas S Kupper; Rachael A Clark
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

8.  Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.

Authors:  Larisa J Geskin; Sara Viragova; Donna B Stolz; Patrizia Fuschiotti
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

9.  Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma.

Authors:  M Di Renzo; P Rubegni; G De Aloe; L Paulesu; A L Pasqui; L Andreassi; A Auteri; M Fimiani
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

10.  Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.

Authors:  B N Lee; M Duvic; C K Tang; C Bueso-Ramos; Z Estrov; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1999-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.